Status In progress
Process MTA
ID number 901

Project Team

Project lead Jeremy Powell

Email enquiries

Evidence Review Group / Assessment Group School of Health and Related Research, University of Sheffield


Companies sponsors Actavis UK (raloxifene) – not participating
  Amgen (denosumab, romosozumab)
  Consilient Health (raloxifene) not participating
  Daiichi Sankyo (raloxifene)
  Eli Lilly (teriparatide)
  Mylan UK (raloxifene) – not participating
  Sandoz (raloxifene) – not participating
  UCB (romosozumab)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups National Osteoporosis Society
Professional groups Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  United Kingdom Clinical Pharmacy Association


Comparator companies Accord Healthcare (alendronate, ibandronate, zoledronate) not participating
  Actavis UK (alendronate, ibandronate, risedronate, zoledronate) not participating
  Amneal Pharma Europe (zoledronate) not participating
  Aurobindo (alendronate, risedronate) not participating
  Consilient Health (ibandronate) not participating
  Creo Pharma (alendronate) not participating
  Dr Reddy’s Laboratories (zoledronate) not participating
  Hospira UK (zoledronate) not participating
  Internis (alendronate) not participating
  Intrapharm Laboratories (zoledronate) not participating
  Medac (zoledronate) not participating
  Merck Sharp & Dohme (alendronate) not participating
  Mylan UK (alendronate, ibandronate, zoledronate) not participating
  Novartis Pharmaceuticals (zoledronate) not participating
  Ranbaxy (ibandronate, zoledronate) not participating
  Rosemont (alendronate) not participating
  Sandoz (risedronate) not participating
  Seacross Pharmaceuticals (zoledronate) not participating
  Warner Chilcott UK (risedronate) not participating
  Zentiva (alendronate, ibandronate) not participating
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Bone Research Society


Key events during the development of the guidance:

Date Update
29 January 2019 All of the drugs in this Technology Appraisal must have received a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) before the first Appraisal Committee meeting. This will not have happened before the current scheduled meeting in February, therefore we will reschedule this appraisal and the first Committee meeting will take place on 24 April 2019.
15 January 2019 Assessment report sent for information
18 May 2018 Invitation to participate
18 December 2017 - 22 January 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
17 June 2016 Further details regarding the timings of this MTA will be available in due course.
01 March 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance